A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients
According to the WHO classification, advanced systemic mastocytosis (advSM) comprises aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL). SM-AHN is the most common subtype of advSM, diagnosed in up to 80% of patients. The AHN is characterized in >90% of patients as a myeloid neoplasm, e.g. CMML. Acquired mutations in KIT (usually KIT D816V) are detectable in >90% of patients. The SM-AHN phenotype is usually based on clonal involvement of KIT D816V in various hematopoietic lineages, e.g. monocytes, eosinophils and other non-mast cell lineages. However, recent data hav...
Source: Blood - November 21, 2018 Category: Hematology Authors: Jawhar, M., Schwaab, J., Naumann, N., Metzgeroth, G., Horny, H.-P., Sotlar, K., Meggendorfer, M., Haferlach, T., Cross, N. C. P., Fabarius, A., Hofmann, W.-K., Valent, P., Reiter, A. Tags: 634. Myeloproliferative Syndromes: Clinical: Addressing Areas of Unmet Need in Prognostic Assessments and Therapy for MPNs Source Type: research
Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease
Relapse of malignancy and lethal graft versus host disease (GVHD) are the principal causes of failure of allogeneic hematopoietic cell transplant (HCT). Recently we have shown that at seven days after HCT an algorithm using two serum biomarkers (ST2 and REG3α) can predict severe GVHD (Hartwell et al. JCI Insight 2017). We determined whether serial testing (in the first month following HCT) of patients with low probability biomarkers would improve the predictive accuracy of the algorithm and identify patients with different risks of relapse and lethal GVHD. Patients who received an HCT at 18 centers in the Mount Sinai...
Source: Blood - November 21, 2018 Category: Hematology Authors: Aziz, M. D., Shah, J., Kapoor, U., Dimopoulos, C. N., Ayuk, F. A., Hogan, W. J., Schreiner, E., Choe, H. K., Chen, Y.-B., Hexner, E. O., Etra, A., Merli, P., Roesler, W., Kitko, C., Qayed, M., Wolfl, M., Mielke, S., Wudhikarn, K., Nakamura, R., Ordemann, Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biomarkers and the Microbiome Source Type: research
Economic Burden of Venous Thromboembolism in Cancer Patients -- a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism
This study was conducted to assess the economic burden of VTE in cancer patients in comparison their non-VTE peers with similar cancer type.All-cause costs over 3-year period were used and included the costs of all services. These were further explored to compare the total cost of care, cost based on the site of utilization of care and pharmacy cost between the patients with VTE with their matched peers. VTE-related costs were identified with a primary or secondary diagnosis of DVT or PE, and were evaluated for the entire follow-up period, starting from the initiation of the anticoagulant therapy until end of eligibility o...
Source: Blood - November 21, 2018 Category: Hematology Authors: Shah, S., Rubin, N., Khorana, A. A. Tags: 901. Health Services Research-Non-Malignant Conditions: Thrombosis and Anticoagulation Source Type: research
Bone Marrow Niche-Derived Extracellular Matrix-Degrading Enzymes Influence the Progression of B-Cell Acute Lymphoblastic Leukemia
Interactions with the bone marrow microenvironment (BMM) influence the pathophysiology of hematological malignancies. Reciprocally, hematological malignancies remodel the BMM in order to render it more hospitable for malignant progression. Hypothesizing that different leukemias differentially remodel stroma cells in the BMM, we tested differences in the expression of various genes in sorted osteoblastic cells from mice with B-cell acute lymphoblastic (B-ALL), acute myeloid (AML) or chronic myeloid leukemia (CML) or control mice by microarray. This revealed a high expression of various proteases, especially matrix metallopr...
Source: Blood - November 21, 2018 Category: Hematology Authors: Verma, D., Zanetti, C., Fontenay, M., Krause, D. S. Tags: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: ALL Risk Associated Genes and Leukemia Infiltration Source Type: research
Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
Patients with the plasma cell malignancy multiple myeloma now benefit from treatments such as proteasome inhibitors, immunomodulatory imide drugs (IMiDs), autologous stem cell transplant, and monoclonal antibodies. However, 20% of patients still relapse or die within two years and are deemed 'high risk'. Current markers fail to identify all high-risk patients resulting in misdiagnoses, therefore additional markers for this deadly form of the disease are required.To better understand and identify high-risk myeloma, we analyzed the structural variant landscape of 826 myelomas from newly-diagnosed patients using whole genome ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Barwick, B. G., Neri, P., Bahlis, N., Nooka, A. K., Kaufman, J. L., Gupta, V. A., Auclair, D., Keats, J. J., Lonial, S., Vertino, P. M., Boise, L. H. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms, Treatment Response, and Survival in Multiple Myeloma Source Type: research
